Immucell (ICCC) Research & Development (2010 - 2026)
Immucell's (ICCC) quarterly Research & Development came in at $1.3 million in Q4 2025, up 228.36% YoY from $386883.0 in Q4 2024, and up 82.97% on a QoQ basis from $694311.0 in Q3 2025.
Immucell (ICCC) Research & Development (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Research & Development data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Research & Development rose 228.36% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.5 million (up 17.07% YoY) and the FY2025 annual result came in at $3.6 million, up 2.52% from the prior year.
- Research & Development advanced to $1.3 million in Q4 2025, from $694311.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.3 million in Q4 2022 to a low of $386883.0 in Q4 2024.
- A 5-year average of $949366.6 and a median of $856658.0 in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2021 — Research & Development plunged 59.79% — and 2025, when it surged 228.36%.
- Tracing ICCC's Research & Development over 5 years: stood at $1.1 million in 2021, then jumped by 110.71% to $2.3 million in 2022, then slumped by 51.29% to $1.1 million in 2023, then plunged by 65.41% to $386883.0 in 2024, then surged by 228.36% to $1.3 million in 2025.
- The last three Research & Development figures came in at $1.3 million (Q4 2025), $694311.0 (Q3 2025), and $696086.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Mn |
| Dec 31, 2025 | 1.27 Mn |
| Sep 30, 2025 | 694,311.00 |
| Jun 30, 2025 | 696,086.00 |
| Mar 31, 2025 | 856,658.00 |
| Dec 31, 2024 | 386,883.00 |
| Sep 30, 2024 | 786,136.00 |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 800,923.00 |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Sep 30, 2022 | 726,738.00 |
| Jun 30, 2022 | 1.14 Mn |
| Mar 31, 2022 | 811,500.00 |
| Dec 31, 2021 | 1.09 Mn |
| Sep 30, 2021 | 656,418.00 |
| Jun 30, 2021 | 436,982.00 |
| Mar 31, 2021 | 1.03 Mn |